Harrow reported a $20 million loss for the first half of 2024, doubling from the previous year. Increased competition from generics and new drugs will squash margins. Harrow's recent strategy shift ...
Thank you, operator. Good morning, and welcome to Harrow's second quarter 2025 earnings conference call. My name is Mike Biega, and I'm excited to be introducing today's call, having joined Harrow as ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results